Radiopharm Theranostics Ltd
Radiopharm Theranostics Ltd is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. on August 30, 2027. There are 5 upcoming events on record.
Cash runway is approximately 9.5 months based on the most recent reported cash position and quarterly operating burn as of 2025-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| August 30, 2027 | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. | Trial Milestone | Phase 1 |
| December 15, 2027 | 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors | Trial Milestone | EARLY_Phase 1 |
| December 15, 2027 | HEAT Trial (HER2 Antibody Therapy With Lutetium-177) | Trial Milestone | EARLY_Phase 1 |
| December 15, 2027 | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors | Trial Milestone | Phase 1/Phase 2 |
| November 30, 2028 | A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC | Trial Milestone | Phase 1/Phase 2 |
Track RADX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open RADX in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.